Value of Gene Therapies

Gene therapies are fundamentally different from medicines that are taken over the course of a patient’s entire lifetime to address the symptoms of disease. Today’s new transformational therapies are designed to target the source of many rare diseases at the genetic level often with one lasting dose. These differences make gene therapies ill-suited for the current tools that are used by payers to determine their cost effectiveness.  

​

As more innovative gene therapies progress toward – and achieve – FDA approval, we must bring new thinking to how they are valued. 

​

Getting the value equation right for gene therapies will have a real and tangible impact on patients’ ability to benefit from this game-changing field.

​

IGT is committed to educating stakeholders about the value of gene therapies, what it looks like to accurately and fully assess their value, and the consequences if we fall short.

​

To start, we worked with our council members to identify the most important elements of value to patients, the healthcare system, and society.